HHS/FDA Announcement Bolsters Else Nutrition's Momentum in Bringing its Infant Formula to Market in the United States VANCOUVER, BC, March 20, 2025 /PRNewswire/ ...
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 Launch preparations on track toward goal ...
Harrow, Inc. stock dropped 50% post Q3 2024, but Q4 previews and FY 2025 projections signal growth potential. Click here to ...
New bipartisan legislation would increase awareness about what’s in food. Products that contain certain dyes and chemicals ...
Clinical data highlight survival benefits and improvement in functional motor outcomes associated with treatment with doxecitine (dC) and ...
A subcommittee advanced a package dubbed the "Florida Farm Bill." Targets include "any additive" to water "for health-related ...
This week is National Poison Prevention Week. New York State leaders are sounding the alarm on safe storage and responsible ...
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
Information on the FDA review process for PMA applications can be found on the FDA website at: https://www.fda.gov/medical-devices/premarket-approval-pma/pma-review-process. There can be no assurance ...
Ad hoc announcement pursuant to Art. 53 LR <li /> FDA confirms that prescribers and pharmacists are no longer expect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback